Reicin Alise, the Chief Executive Officer of Tectonic Therapeutic, Inc., has reported a stock transaction that underscores her ongoing commitment to the company. The recent filing with the SEC indicates that Alise acquired shares to satisfy tax withholding obligations related to the vesting of restricted stock units. This move is significant as it reflects her investment in Tectonic's future and could influence perceptions within the biological products sector.
Background
Tectonic Therapeutic, Inc. is a company operating in the biological products industry, specifically classified under the SIC code 2836. The company, based in Watertown, Massachusetts, focuses on developing innovative therapies. Tectonic has undergone name changes in the past, previously known as AvroBio, Inc. The most recent filing was submitted on October 2, 2026, and is part of a series of transactions reported by Alise.
What the Filing Says
The SEC filing reveals that on September 25, 2026, Alise acquired 1,545 shares of common stock at a price of $23.67 per share. This transaction was reported as a disposal of shares to meet tax obligations associated with the vesting of restricted stock units granted a year prior. Following this transaction, Alise holds a total of 309,078 shares directly and an additional 127,030 shares indirectly through the Reicin-Boiarsky Family Trust, where she shares voting power with her spouse.
Impact
This transaction may affect Tectonic's stakeholders, including investors and employees, as it demonstrates Alise's confidence in the company's direction. It also highlights the importance of tax planning for executives in the biotech field, as they navigate stock compensation and personal financial strategies.
What's Next
The filing does not say what happens next.